FDA label 9237e819-2f88-4a80-bfc5-471564bf67ad

WARNINGS Safe use of leuprolide acetate or norethindrone acetate in pregnancy has not been established clinically. Before starting treatment with LUPRON DEPOT, pregnancy must be excluded. When used monthly at the recommended dose, LUPRON DEPOT usually inhibits ovulation and stops menstruation. Contraception is not insured, however, by taking LUPRON DEPOT. Therefore, patients should use non-hormonal methods of contraception. Patients should be advised to see their physician if they believe they may be pregnant. If a patient becomes pregnant during treatment, the drug must be discontinued and the patient must be apprised of the potential risk to the fetus. During the early phase of therapy, sex steroids temporarily rise above baseline because of the physiologic effect of the drug. Therefore, an increase in clinical signs and symptoms may be observed during the initial days of therapy, but these will dissipate with continued therapy. Symptoms consistent with an anaphylactoid or asthmatic process have been rarely reported post-marketing. The following applies to co-treatment with LUPRON and norethindrone acetate: Norethindrone acetate treatment should be discontinued if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be withdrawn. Because of the occasional occurrence of thrombophlebitis and pulmonary embolism in patients taking progestogens, the physician should be alert to the earliest manifestations of the disease in women taking norethindrone acetate. Assessment and management of risk factors for cardiovascular disease is recommended prior to initiation of add-back therapy with norethindrone acetate. Norethindrone acetate should be used with caution in women with risk factors, including lipid abnormalities or cigarette smoking.

ADVERSE REACTIONS Clinical Trials Estradiol levels may increase during the first weeks following the initial injection of LUPRON, but then decline to menopausal levels. This transient increase in estradiol can be associated with a temporary worsening of signs and symptoms (see WARNINGS section). As would be expected with a drug that lowers serum estradiol levels, the most frequently reported adverse reactions were those related to hypoestrogenism. The monthly formulation of LUPRON DEPOT 3.75 mg was utilized in controlled clinical trials that studied the drug in 166 endometriosis and 166 uterine fibroids patients. Adverse events reported in ≥5% of patients in either of these populations and thought to be potentially related to drug are noted in the following table. Table 2 ADVERSE EVENTS REPORTED TO BE CAUSALLY RELATED TO DRUG IN ≥ 5% OF PATIENTS Endometriosis (2 Studies) Uterine Fibroids (4 Studies) LUPRON DEPOT 3.75 mg N=166 Danazol N=136 Placebo N=31 LUPRON DEPOT 3.75 mg N=166 Placebo N=163 N (%) N (%) N (%) N (%) N (%) Body as a Whole Asthenia 5 (3) 9 (7) 0 (0) 14 (8.4) 8 (4.9) General pain 31 (19) 22 (16) 1 (3) 14 (8.4) 10 (6.1) Headache* 53 (32) 30 (22) 2 (6) 43 (25.9) 29 (17.8) Cardiovascular System Hot flashes/sweats* 139 (84) 77 (57) 9 (29) 121 (72.9) 29 (17.8) Gastrointestinal System Nausea/vomiting 21 (13) 17 (13) 1 (3) 8 (4.8) 6 (3.7) GI disturbances* 11 (7) 8 (6) 1 (3) 5 (3.0) 2 (1.2) Metabolic and Nutritional Disorders Edema 12 (7) 17 (13) 1 (3) 9 (5.4) 2 (1.2) Weight gain/loss 22 (13) 36 (26) 0 (0) 5 (3.0) 2 (1.2) Endocrine System Acne 17 (10) 27 (20) 0 (0) 0 (0) 0 (0) Hirsutism 2 (1) 9 (7) 1 (3) 1 (0.6) 0 (0) Musculoskeletal System Joint disorder* 14 (8) 11 (8) 0 (0) 13 (7.8) 5 (3.1) Myalgia* 1 (1) 7 (5) 0 (0) 1 (0.6) 0 (0) Nervous System Decreased libido* 19 (11) 6 (4) 0 (0) 3 (1.8) 0 (0) Depression/emotional lability* 36 (22) 27 (20) 1 (3) 18 (10.8) 7 (4.3) Dizziness 19 (11) 4 (3) 0 (0) 3 (1.8) 6 (3.7) Nervousness* 8 (5) 11 (8) 0 (0) 8 (4.8) 1 (0.6) Neuromuscular disorders* 11 (7) 17 (13) 0 (0) 3 (1.8) 0 (0) Paresthesias 12 (7) 11 (8) 0 (0) 2 (1.2) 1 (0.6) Skin and Appendages Skin reactions 17 (10) 20 (15) 1 (3) 5 (3.0) 2 (1.2) Urogenital System Breast changes/tenderness/pain* 10 (6) 12 (9) 0 (0) 3 (1.8) 7 (4.3) Vaginitis* 46 (28) 23 (17) 0 (0) 19 (11.4) 3 (1.8) In these same studies, symptoms reported in <5% of patients included: Body as a Whole - Body odor, Flu syndrome, Injection site reactions; Cardiovascular System - Palpitations, Syncope, Tachycardia; Digestive System - Appetite changes, Dry mouth, Thirst; Endocrine System - Androgen-like effects; Hemic and Lymphatic System - Ecchymosis, Lymphadenopathy; Nervous System – Anxiety*, Insomnia/Sleep disorders*, Delusions, Memory disorder, Personality disorder; Respiratory System - Rhinitis; Skin and Appendages - Alopecia, Hair disorder, Nail disorder; Special Senses - Conjunctivitis, Ophthalmologic disorders*, Taste perversion; Urogenital System - Dysuria*, Lactation, Menstrual disorders. * = Possible effect of decreased estrogen. In one controlled clinical trial utilizing the monthly formulation of LUPRON DEPOT, patients diagnosed with uterine fibroids received a higher dose (7.5 mg) of LUPRON DEPOT. Events seen with this dose that were thought to be potentially related to drug and were not seen at the lower dose included glossitis, hypesthesia, lactation, pyelonephritis, and urinary disorders. Generally, a higher incidence of hypoestrogenic effects was observed at the higher dose. Table 3 lists the potentially drug-related adverse events observed in at least 5% of patients in any treatment group during the first 6 months of treatment in the add-back clinical studies. In the controlled clinical trial, 50 of 51 (98%) patients in the LD group and 48 of 55 (87%) patients in the LD/N group reported experiencing hot flashes on one or more occasions during treatment. During Month 6 of treatment, 32 of 37 (86%) patients in the LD group and 22 of 38 (58%) patients in the LD/N group reported having experienced hot flashes. The mean number of days on which hot flashes were reported during this month of treatment was 19 and 7 in the LD and LD/N treatment groups, respectively. The mean maximum number of hot flashes in a day during this month of treatment was 5.8 and 1.9 in the LD and LD/N treatment groups, respectively. Table 3 TREATMENT-RELATED ADVERSE EVENTS OCCURRING IN ≥5% OF PATIENTS Controlled Study Open Label Study LD - Only* N=51 LD/N† N=55 LD/N† N=136 Adverse Events N (%) N (%) N (%) Any Adverse Event 50 (98) 53 (96) 126 (93) Body as a Whole Asthenia 9 (18) 10 (18) 15 (11) Headache/Migraine 33 (65) 28 (51) 63 (46) Injection Site Reaction 1 (2) 5 (9) 4 (3) Pain 12 (24) 16 (29) 29 (21) Cardiovascular System Hot flashes/sweats 50 (98) 48 (87) 78 (57) Digestive System Altered Bowel Function 7 (14) 8 (15) 14 (10) Changes in Appetite 2 (4) 0 (0) 8 (6) GI Disturbance 2 (4) 4 (7) 6 (4) Nausea/Vomiting 13 (25) 16 (29) 17 (13) Metabolic and Nutritional Disorders Edema 0 (0) 5 (9) 9 (7) Weight Changes 6 (12) 7 (13) 6 (4) Nervous System Anxiety 3 (6) 0 (0) 11 (8) Depression/Emotional Lability 16 (31) 15 (27) 46 (34) Dizziness/Vertigo 8 (16) 6 (11) 10 (7) Insomnia/Sleep Disorder 16 (31) 7 (13) 20 (15) Libido Changes 5 (10) 2 (4) 10 (7) Memory Disorder 3 (6) 1 (2) 6 (4) Nervousness 4 (8) 2 (4) 15 (11) Neuromuscular Disorder 1 (2) 5 (9) 4 (3) Skin and Appendages Alopecia 0 (0) 5 (9) 4 (3) Androgen-Like Effects 2 (4) 3 (5) 24 (18) Skin/Mucous Membrane Reaction 2 (4) 5 (9) 15 (11) Urogenital System Breast Changes/Pain/Tenderness 3 (6) 7 (13) 11 (8) Menstrual Disorders 1 (2) 0 (0) 7 (5) Vaginitis 10 (20) 8 (15) 11 (8) * LD-Only = LUPRON DEPOT 3.75 mg † LD/N = LUPRON DEPOT 3.75 mg plus norethindrone acetate 5 mg Changes in Bone Density In controlled clinical studies, patients with endometriosis (six months of therapy) or uterine fibroids (three months of therapy) were treated with LUPRON DEPOT 3.75 mg. In endometriosis patients, vertebral bone density as measured by dual energy x-ray absorptiometry (DEXA) decreased by an average of 3.2% at six months compared with the pretreatment value. Clinical studies demonstrate that concurrent hormonal therapy (norethindrone acetate 5 mg daily) and calcium supplementation is effective in significantly reducing the loss of bone mineral density that occurs with LUPRON treatment, without compromising the efficacy of LUPRON in relieving symptoms of endometriosis. LUPRON DEPOT 3.75 mg plus norethindrone acetate 5 mg daily was evaluated in two clinical trials. The results from this regimen were similar in both studies. LUPRON DEPOT 3.75 mg was used as a control group in one study. The bone mineral density data of the lumbar spine from these two studies are presented in Table 4. Table 4 MEAN PERCENT CHANGE FROM BASELINE IN BONE MINERAL DENSITY OF LUMBAR SPINE LUPRON DEPOT 3.75mg LUPRON DEPOT 3.75 mg plus norethindrone acetate 5 mg daily Controlled Study Controlled Study Open Label Study N Change (Mean, 95% CI) # N Change (Mean, 95% CI) # N Change (Mean, 95% CI) # Week 24* 41 -3.2% (-3.8, -2.6) 42 -0.3% (-0.8, 0.3) 115 -0.2% (-0.6, 0.2) Week 52† 29 -6.3% (-7.1, -5.4) 32 -1.0% (-1.9, -0.1) 84 -1.1% (-1.6, -0.5) * Includes on-treatment measurements that fell within 2–252 days after the first day of treatment. † Includes on-treatment measurements >252 days after the first day of treatment. # 95% CI: 95% Confidence Interval When LUPRON DEPOT 3.75 mg was administered for three months in uterine fibroid patients, vertebral trabecular bone mineral density as assessed by quantitative digital radiography (QDR) revealed a mean decrease of 2.7% compared with baseline. Six months after discontinuation of therapy, a trend toward recovery was observed. Use of LUPRON DEPOT for longer than three months (uterine fibroids) or six months (endometriosis) or in the presence of other known risk factors for decreased bone mineral content may cause additional bone loss and is not recommended . Changes in Laboratory Values During Treatment Plasma Enzymes Endometriosis During early clinical trials with LUPRON DEPOT 3.75 mg, regular laboratory monitoring revealed that AST levels were more than twice the upper limit of normal in only one patient. There was no clinical or other laboratory evidence of abnormal liver function. In two other clinical trials, 6 of 191 patients receiving LUPRON DEPOT 3.75 mg plus norethindrone acetate 5 mg daily for up to 12 months developed an elevated (at least twice the upper limit of normal) SGPT or GGT. Five of the 6 increases were observed beyond 6 months of treatment. None were associated with elevated bilirubin concentration. Uterine Leiomyomata (Fibroids) In clinical trials with LUPRON DEPOT 3.75 mg, five (3%) patients had a post-treatment transaminase value that was at least twice the baseline value and above the upper limit of the normal range. None of the laboratory increases were associated with clinical symptoms. Lipids Endometriosis In earlier clinical studies, 4% of the LUPRON DEPOT 3.75 mg patients and 1% of the danazol patients had total cholesterol values above the normal range at enrollment. These patients also had cholesterol values above the normal range at the end of treatment. Of those patients whose pretreatment cholesterol values were in the normal range, 7% of the LUPRON DEPOT 3.75 mg patients and 9% of the danazol patients had post-treatment values above the normal range. The mean (±SEM) pretreatment values for total cholesterol from all patients were 178.8 (2.9) mg/dL in the LUPRON DEPOT 3.75 mg groups and 175.3 (3.0) mg/dL in the danazol group. At the end of treatment, the mean values for total cholesterol from all patients were 193.3 mg/dL in the LUPRON DEPOT 3.75 mg group and 194.4 mg/dL in the danazol group. These increases from the pretreatment values were statistically significant (p<0.03) in both groups. Triglycerides were increased above the upper limit of normal in 12% of the patients who received LUPRON DEPOT 3.75 mg and in 6% of the patients who received danazol. At the end of treatment, HDL cholesterol fractions decreased below the lower limit of the normal range in 2% of the LUPRON DEPOT 3.75 mg patients compared with 54% of those receiving danazol. LDL cholesterol fractions increased above the upper limit of the normal range in 6% of the patients receiving LUPRON DEPOT 3.75 mg compared with 23% of those receiving danazol. There was no increase in the LDL/HDL ratio in patients receiving LUPRON DEPOT 3.75 mg but there was approximately a two-fold increase in the LDL/HDL ratio in patients receiving danazol. In two other clinical trials, LUPRON DEPOT 3.75 mg plus norethindrone acetate 5 mg daily was evaluated for 12 months of treatment. LUPRON DEPOT 3.75 mg was used as a control group in one study. Percent changes from baseline for serum lipids and percentages of patients with serum lipid values outside of the normal range in the two studies are summarized in the tables below. Table 5 SERUM LIPIDS: MEAN PERCENT CHANGES FROM BASELINE VALUES AT TREATMENT WEEK 24 LUPRON LUPRON plus norethindrone acetate 5 mg daily Controlled Study (n=39) Controlled Study (n=41) Open Label Study (n=117) Baseline Value* Wk 24 % Change Baseline Value* Wk 24 % Change Baseline Value* Wk 24 % Change Total Cholesterol 170.5 9.2% 179.3 0.2% 181.2 2.8% HDL Cholesterol 52.4 7.4% 51.8 -18.8% 51.0 -14.6% LDL Cholesterol 96.6 10.9% 101.5 14.1% 109.1 13.1% LDL/HDL Ratio 2.0† 5.0% 2.1† 43.4% 2.3† 39.4% Triglycerides 107.8 17.5% 130.2 9.5% 105.4 13.8% * mg/dL † ratio Changes from baseline tended to be greater at Week 52. After treatment, mean serum lipid levels from patients with follow up data returned to pretreatment values. Table 6 PERCENTAGE OF PATIENTS WITH SERUM LIPID VALUES OUTSIDE OF THE NORMAL RANGE LUPRON LUPRON plus norethindrone acetate 5 mg daily Controlled Study (n=39) Controlled Study (n=41) Open Label Study (n=117) Wk 0 Wk 24* Wk 0 Wk 24* Wk 0 Wk 24* Total Cholesterol (>240 mg/dL) 15% 23% 15% 20% 6% 7% HDL Cholesterol (<40 mg/dL) 15% 10% 15% 44% 15% 41% LDL Cholesterol (>160 mg/dL) 0% 8% 5% 7% 9% 11% LDL/HDL Ratio (>4.0) 0% 3% 2% 15% 7% 21% Triglycerides (>200 mg/dL) 13% 13% 12% 10% 5% 9% * Includes all patients regardless of baseline value. Low HDL-cholesterol (<40 mg/dL) and elevated LDL-cholesterol (>160 mg/dL) are recognized risk factors for cardiovascular disease. The long-term significance of the observed treatment-related changes in serum lipids in women with endometriosis is unknown. Therefore assessment of cardiovascular risk factors should be considered prior to initiation of concurrent treatment with LUPRON and norethindrone acetate. Uterine Leiomyomata (Fibroids) In patients receiving LUPRON DEPOT 3.75 mg, mean changes in cholesterol (+11 mg/dL to +29 mg/dL), LDL cholesterol (+8 mg/dL to +22 mg/dL), HDL cholesterol (0 to +6 mg/dL), and the LDL/HDL ratio (-0.1 to +0.5) were observed across studies. In the one study in which triglycerides were determined, the mean increase from baseline was 32 mg/dL. Other Changes Endometriosis The following changes were seen in approximately 5% to 8% of patients. In the earlier comparative studies, LUPRON DEPOT 3.75 mg was associated with elevations of LDH and phosphorus, and decreases in WBC counts. Danazol therapy was associated with increases in hematocrit, platelet count, and LDH. In the hormonal add-back studies LUPRON DEPOT in combination with norethindrone acetate was associated with elevations of GGT and SGPT. Uterine Leiomyomata (Fibroids) Hematology: (see CLINICAL STUDIES section) In LUPRON DEPOT 3.75 mg treated patients, although there were statistically significant mean decreases in platelet counts from baseline to final visit, the last mean platelet counts were within the normal range. Decreases in total WBC count and neutrophils were observed, but were not clinically significant. Chemistry: Slight to moderate mean increases were noted for glucose, uric acid, BUN, creatinine, total protein, albumin, bilirubin, alkaline phosphatase, LDH, calcium, and phosphorus. None of these increases were clinically significant. Postmarketing During postmarketing surveillance, the following adverse events were reported. Like other drugs in this class, mood swings, including depression, have been reported. There have been rare reports of suicidal ideation and attempt. Many, but not all, of these patients had a history of depression or other psychiatric illness. Patients should be counseled on the possibility of development or worsening of depression during treatment with LUPRON. Symptoms consistent with an anaphylactoid or asthmatic process have been rarely reported. Rash, urticaria, and photosensitivity reactions have also been reported. Localized reactions including induration and abscess have been reported at the site of injection. Symptoms consistent with fibromyalgia (eg: joint and muscle pain, headaches, sleep disorder, gastrointestinal distress, and shortness of breath) have been reported individually and collectively. Other events reported are: Cardiovascular System – Hypotension; Cases of serious venous and arterial thromboembolism have been reported, including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and transient ischemic attack. Although a temporal relationship was reported in some cases, most cases were confounded by risk factors or concomitant medication use. It is unknown if there is a causal association between the use of GnRH analogs and these events. Hemic and Lymphatic System - Decreased WBC; Central/Peripheral Nervous System - Convulsion, Peripheral neuropathy, Spinal fracture/paralysis; Musculoskeletal System - Tenosynovitis-like symptoms; Urogenital System - Prostate pain. Pituitary apoplexy During post-marketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed, with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required. See other LUPRON DEPOT and LUPRON Injection package inserts for other events reported in different patient populations.

<table ID="t31013213" width="100%"> <caption>Table 2 ADVERSE EVENTS REPORTED TO BE CAUSALLY RELATED TO DRUG IN &#x2265; 5% OF PATIENTS</caption> <colgroup> <col width="25*"/> <col width="7*"/> <col width="7*"/> <col width="7*"/> <col width="7*"/> <col width="7*"/> <col width="7*"/> <col width="7*"/> <col width="7*"/> <col width="7*"/> <col width="7*"/> </colgroup> <tbody> <tr> <td styleCode="Toprule" align="center" valign="top"> </td> <td styleCode="Toprule" colspan="6" align="center" valign="top"> <content styleCode="bold">Endometriosis (2 Studies)</content> </td> <td styleCode="Toprule Lrule" colspan="4" align="center" valign="top"> <content styleCode="bold">Uterine Fibroids (4 Studies)</content> </td> </tr> <tr> <td styleCode="Toprule" align="center" valign="top"> </td> <td styleCode="Toprule" colspan="2" align="center" valign="top"> <content styleCode="bold">LUPRON DEPOT 3.75 mg N=166</content> </td> <td styleCode="Toprule" colspan="2" align="center" valign="top"> <content styleCode="bold">Danazol N=136</content> </td> <td styleCode="Toprule" colspan="2" align="center" valign="top"> <content styleCode="bold">Placebo N=31</content> </td> <td styleCode="Toprule Lrule" colspan="2" align="center" valign="top"> <content styleCode="bold">LUPRON DEPOT 3.75 mg N=166</content> </td> <td styleCode="Toprule" colspan="2" align="center" valign="top"> <content styleCode="bold">Placebo N=163</content> </td> </tr> <tr> <td> </td> <td align="center" valign="top"> <content styleCode="bold">N</content> </td> <td align="center" valign="top"> <content styleCode="bold">(%)</content> </td> <td align="center" valign="top"> <content styleCode="bold">N</content> </td> <td align="center" valign="top"> <content styleCode="bold">(%)</content> </td> <td align="center" valign="top"> <content styleCode="bold">N</content> </td> <td align="center" valign="top"> <content styleCode="bold">(%)</content> </td> <td styleCode="Lrule" align="center" valign="top"> <content styleCode="bold">N</content> </td> <td align="center" valign="top"> <content styleCode="bold">(%)</content> </td> <td align="center" valign="top"> <content styleCode="bold">N</content> </td> <td align="center" valign="top"> <content styleCode="bold">(%)</content> </td> </tr> <tr> <td styleCode="Toprule" align="left">Body as a Whole</td> <td styleCode="Toprule" align="center"> </td> <td styleCode="Toprule" align="center"> </td> <td styleCode="Toprule" align="center"> </td> <td styleCode="Toprule" align="center"> </td> <td styleCode="Toprule" align="center"> </td> <td styleCode="Toprule" align="center"> </td> <td styleCode="Toprule Lrule" align="center"> </td> <td styleCode="Toprule" align="center"> </td> <td styleCode="Toprule" align="center"> </td> <td styleCode="Toprule" align="center"> </td> </tr> <tr> <td align="left"> Asthenia</td> <td align="center">5</td> <td align="center">(3)</td> <td align="center">9</td> <td align="center">(7)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">14</td> <td align="center">(8.4)</td> <td align="center">8</td> <td align="center">(4.9)</td> </tr> <tr> <td align="left"> General pain</td> <td align="center">31</td> <td align="center">(19)</td> <td align="center">22</td> <td align="center">(16)</td> <td align="center">1</td> <td align="center">(3)</td> <td styleCode="Lrule" align="center">14</td> <td align="center">(8.4)</td> <td align="center">10</td> <td align="center">(6.1)</td> </tr> <tr> <td align="left"> Headache*</td> <td align="center">53</td> <td align="center">(32)</td> <td align="center">30</td> <td align="center">(22)</td> <td align="center">2</td> <td align="center">(6)</td> <td styleCode="Lrule" align="center">43</td> <td align="center">(25.9)</td> <td align="center">29</td> <td align="center">(17.8)</td> </tr> <tr> <td align="left">Cardiovascular System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td styleCode="Lrule" align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr> <td align="left"> Hot flashes/sweats*</td> <td align="center">139</td> <td align="center">(84)</td> <td align="center">77</td> <td align="center">(57)</td> <td align="center">9</td> <td align="center">(29)</td> <td styleCode="Lrule" align="center">121</td> <td align="center">(72.9)</td> <td align="center">29</td> <td align="center">(17.8)</td> </tr> <tr> <td align="left">Gastrointestinal System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td styleCode="Lrule" align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr> <td align="left"> Nausea/vomiting</td> <td align="center">21</td> <td align="center">(13)</td> <td align="center">17</td> <td align="center">(13)</td> <td align="center">1</td> <td align="center">(3)</td> <td styleCode="Lrule" align="center">8</td> <td align="center">(4.8)</td> <td align="center">6</td> <td align="center">(3.7)</td> </tr> <tr> <td align="left"> GI disturbances*</td> <td align="center">11</td> <td align="center">(7)</td> <td align="center">8</td> <td align="center">(6)</td> <td align="center">1</td> <td align="center">(3)</td> <td styleCode="Lrule" align="center">5</td> <td align="center">(3.0)</td> <td align="center">2</td> <td align="center">(1.2)</td> </tr> <tr> <td align="left">Metabolic and Nutritional Disorders</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td styleCode="Lrule" align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr> <td align="left"> Edema</td> <td align="center">12</td> <td align="center">(7)</td> <td align="center">17</td> <td align="center">(13)</td> <td align="center">1</td> <td align="center">(3)</td> <td styleCode="Lrule" align="center">9</td> <td align="center">(5.4)</td> <td align="center">2</td> <td align="center">(1.2)</td> </tr> <tr> <td align="left"> Weight gain/loss</td> <td align="center">22</td> <td align="center">(13)</td> <td align="center">36</td> <td align="center">(26)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">5</td> <td align="center">(3.0)</td> <td align="center">2</td> <td align="center">(1.2)</td> </tr> <tr> <td align="left">Endocrine System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td styleCode="Lrule" align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr> <td align="left"> Acne</td> <td align="center">17</td> <td align="center">(10)</td> <td align="center">27</td> <td align="center">(20)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">0</td> <td align="center">(0)</td> <td align="center">0</td> <td align="center">(0)</td> </tr> <tr> <td align="left"> Hirsutism</td> <td align="center">2</td> <td align="center">(1)</td> <td align="center">9</td> <td align="center">(7)</td> <td align="center">1</td> <td align="center">(3)</td> <td styleCode="Lrule" align="center">1</td> <td align="center">(0.6)</td> <td align="center">0</td> <td align="center">(0)</td> </tr> <tr> <td align="left">Musculoskeletal System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td styleCode="Lrule" align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr> <td align="left"> Joint disorder*</td> <td align="center">14</td> <td align="center">(8)</td> <td align="center">11</td> <td align="center">(8)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">13</td> <td align="center">(7.8)</td> <td align="center">5</td> <td align="center">(3.1)</td> </tr> <tr> <td align="left"> Myalgia* </td> <td align="center">1</td> <td align="center">(1)</td> <td align="center">7</td> <td align="center">(5)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">1</td> <td align="center">(0.6)</td> <td align="center">0</td> <td align="center">(0)</td> </tr> <tr> <td align="left">Nervous System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td styleCode="Lrule" align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr> <td align="left"> Decreased libido* </td> <td align="center">19</td> <td align="center">(11)</td> <td align="center">6</td> <td align="center">(4)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">3</td> <td align="center">(1.8)</td> <td align="center">0</td> <td align="center">(0)</td> </tr> <tr> <td align="left"> Depression/emotional lability*</td> <td align="center">36</td> <td align="center">(22)</td> <td align="center">27</td> <td align="center">(20)</td> <td align="center">1</td> <td align="center">(3)</td> <td styleCode="Lrule" align="center">18</td> <td align="center">(10.8)</td> <td align="center">7</td> <td align="center">(4.3)</td> </tr> <tr> <td align="left"> Dizziness</td> <td align="center">19</td> <td align="center">(11)</td> <td align="center">4</td> <td align="center">(3)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">3</td> <td align="center">(1.8)</td> <td align="center">6</td> <td align="center">(3.7)</td> </tr> <tr> <td align="left"> Nervousness*</td> <td align="center">8</td> <td align="center">(5)</td> <td align="center">11</td> <td align="center">(8)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">8</td> <td align="center">(4.8)</td> <td align="center">1</td> <td align="center">(0.6)</td> </tr> <tr> <td align="left"> Neuromuscular disorders*</td> <td align="center">11</td> <td align="center">(7)</td> <td align="center">17</td> <td align="center">(13)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">3</td> <td align="center">(1.8)</td> <td align="center">0</td> <td align="center">(0)</td> </tr> <tr> <td align="left"> Paresthesias</td> <td align="center">12</td> <td align="center">(7)</td> <td align="center">11</td> <td align="center">(8)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">2</td> <td align="center">(1.2)</td> <td align="center">1</td> <td align="center">(0.6)</td> </tr> <tr> <td align="left">Skin and Appendages</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td styleCode="Lrule" align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr> <td align="left"> Skin reactions</td> <td align="center">17</td> <td align="center">(10)</td> <td align="center">20</td> <td align="center">(15)</td> <td align="center">1</td> <td align="center">(3)</td> <td styleCode="Lrule" align="center">5</td> <td align="center">(3.0)</td> <td align="center">2</td> <td align="center">(1.2)</td> </tr> <tr> <td align="left">Urogenital System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td styleCode="Lrule" align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr> <td align="left"> Breast changes/tenderness/pain*</td> <td align="center">10</td> <td align="center">(6)</td> <td align="center">12</td> <td align="center">(9)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">3</td> <td align="center">(1.8)</td> <td align="center">7</td> <td align="center">(4.3)</td> </tr> <tr> <td align="left"> Vaginitis*</td> <td align="center">46</td> <td align="center">(28)</td> <td align="center">23</td> <td align="center">(17)</td> <td align="center">0</td> <td align="center">(0)</td> <td styleCode="Lrule" align="center">19</td> <td align="center">(11.4)</td> <td align="center">3</td> <td align="center">(1.8)</td> </tr> <tr> <td styleCode="Toprule" colspan="11">In these same studies, symptoms reported in &lt;5% of patients included: <content styleCode="italics">Body as a Whole</content> - Body odor, Flu syndrome, Injection site reactions; <content styleCode="italics">Cardiovascular System</content> - Palpitations, Syncope, Tachycardia; <content styleCode="italics">Digestive System</content> - Appetite changes, Dry mouth, Thirst; <content styleCode="italics">Endocrine System</content> - Androgen-like effects; <content styleCode="italics">Hemic and Lymphatic System</content> - Ecchymosis, Lymphadenopathy; <content styleCode="italics">Nervous System</content> &#x2013; Anxiety*, Insomnia/Sleep disorders*, Delusions, Memory disorder, Personality disorder; <content styleCode="italics">Respiratory System</content> - Rhinitis; <content styleCode="italics">Skin and Appendages</content> - Alopecia, Hair disorder, Nail disorder; <content styleCode="italics">Special Senses</content> - Conjunctivitis, Ophthalmologic disorders*, Taste perversion; <content styleCode="italics">Urogenital System</content> - Dysuria*, Lactation, Menstrual disorders.</td> </tr> <tr> <td colspan="11">* = Possible effect of decreased estrogen.</td> </tr> </tbody> </table>

<table ID="t23522213" width="100%"> <caption>Table 3 TREATMENT-RELATED ADVERSE EVENTS OCCURRING IN &#x2265;5% OF PATIENTS</caption> <colgroup> <col width="29*"/> <col width="10*"/> <col width="10*"/> <col width="10*"/> <col width="10*"/> <col width="10*"/> <col width="10*"/> </colgroup> <tbody> <tr valign="top"> <td styleCode="Toprule Botrule"> </td> <td styleCode="Toprule Botrule" colspan="4" align="center"> <content styleCode="bold">Controlled Study</content> </td> <td styleCode="Toprule Botrule" colspan="2" align="center"> <content styleCode="bold">Open Label Study</content> </td> </tr> <tr valign="top"> <td> </td> <td colspan="2" align="center"> <content styleCode="bold">LD - Only* N=51</content> </td> <td colspan="2" align="center"> <content styleCode="bold">LD/N&#x2020; N=55</content> </td> <td colspan="2" align="center"> <content styleCode="bold">LD/N&#x2020; N=136</content> </td> </tr> <tr valign="top"> <td styleCode="Botrule" align="left"> <content styleCode="bold">Adverse Events</content> </td> <td styleCode="Botrule" align="center"> <content styleCode="bold">N</content> </td> <td styleCode="Botrule" align="center"> <content styleCode="bold">(%)</content> </td> <td styleCode="Botrule" align="center"> <content styleCode="bold">N</content> </td> <td styleCode="Botrule" align="center"> <content styleCode="bold">(%)</content> </td> <td styleCode="Botrule" align="center"> <content styleCode="bold">N</content> </td> <td styleCode="Botrule" align="center"> <content styleCode="bold">(%)</content> </td> </tr> <tr valign="top"> <td align="left"> <content styleCode="italics">Any Adverse Event</content> </td> <td align="center">50</td> <td align="center">(98)</td> <td align="center">53</td> <td align="center">(96)</td> <td align="center">126</td> <td align="center">(93)</td> </tr> <tr valign="top"> <td align="left">Body as a Whole</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr valign="top"> <td align="left"> Asthenia</td> <td align="center">9</td> <td align="center">(18)</td> <td align="center">10</td> <td align="center">(18)</td> <td align="center">15</td> <td align="center">(11)</td> </tr> <tr valign="top"> <td align="left"> Headache/Migraine</td> <td align="center">33</td> <td align="center">(65)</td> <td align="center">28</td> <td align="center">(51)</td> <td align="center">63</td> <td align="center">(46)</td> </tr> <tr valign="top"> <td align="left"> Injection Site Reaction</td> <td align="center">1</td> <td align="center">(2)</td> <td align="center">5</td> <td align="center">(9)</td> <td align="center">4</td> <td align="center">(3)</td> </tr> <tr valign="top"> <td align="left"> Pain</td> <td align="center">12</td> <td align="center">(24)</td> <td align="center">16</td> <td align="center">(29)</td> <td align="center">29</td> <td align="center">(21)</td> </tr> <tr valign="top"> <td align="left">Cardiovascular System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr valign="top"> <td align="left"> Hot flashes/sweats</td> <td align="center">50</td> <td align="center">(98)</td> <td align="center">48</td> <td align="center">(87)</td> <td align="center">78</td> <td align="center">(57)</td> </tr> <tr valign="top"> <td align="left">Digestive System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr valign="top"> <td align="left"> Altered Bowel Function</td> <td align="center">7</td> <td align="center">(14)</td> <td align="center">8</td> <td align="center">(15)</td> <td align="center">14</td> <td align="center">(10)</td> </tr> <tr valign="top"> <td align="left"> Changes in Appetite</td> <td align="center">2</td> <td align="center">(4)</td> <td align="center">0</td> <td align="center">(0)</td> <td align="center">8</td> <td align="center">(6)</td> </tr> <tr valign="top"> <td align="left"> GI Disturbance</td> <td align="center">2</td> <td align="center">(4)</td> <td align="center">4</td> <td align="center">(7)</td> <td align="center">6</td> <td align="center">(4)</td> </tr> <tr valign="top"> <td align="left"> Nausea/Vomiting</td> <td align="center">13</td> <td align="center">(25)</td> <td align="center">16</td> <td align="center">(29)</td> <td align="center">17</td> <td align="center">(13)</td> </tr> <tr valign="top"> <td align="left">Metabolic and Nutritional Disorders</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr valign="top"> <td align="left"> Edema</td> <td align="center">0</td> <td align="center">(0)</td> <td align="center">5</td> <td align="center">(9)</td> <td align="center">9</td> <td align="center">(7)</td> </tr> <tr valign="top"> <td align="left"> Weight Changes</td> <td align="center">6</td> <td align="center">(12)</td> <td align="center">7</td> <td align="center">(13)</td> <td align="center">6</td> <td align="center">(4)</td> </tr> <tr valign="top"> <td align="left">Nervous System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr valign="top"> <td align="left"> Anxiety</td> <td align="center">3</td> <td align="center">(6)</td> <td align="center">0</td> <td align="center">(0)</td> <td align="center">11</td> <td align="center">(8)</td> </tr> <tr valign="top"> <td align="left"> Depression/Emotional Lability</td> <td align="center">16</td> <td align="center">(31)</td> <td align="center">15</td> <td align="center">(27)</td> <td align="center">46</td> <td align="center">(34)</td> </tr> <tr valign="top"> <td align="left"> Dizziness/Vertigo</td> <td align="center">8</td> <td align="center">(16)</td> <td align="center">6</td> <td align="center">(11)</td> <td align="center">10</td> <td align="center">(7)</td> </tr> <tr valign="top"> <td align="left"> Insomnia/Sleep Disorder</td> <td align="center">16</td> <td align="center">(31)</td> <td align="center">7</td> <td align="center">(13)</td> <td align="center">20</td> <td align="center">(15)</td> </tr> <tr valign="top"> <td align="left"> Libido Changes</td> <td align="center">5</td> <td align="center">(10)</td> <td align="center">2</td> <td align="center">(4)</td> <td align="center">10</td> <td align="center">(7)</td> </tr> <tr valign="top"> <td align="left"> Memory Disorder</td> <td align="center">3</td> <td align="center">(6)</td> <td align="center">1</td> <td align="center">(2)</td> <td align="center">6</td> <td align="center">(4)</td> </tr> <tr valign="top"> <td align="left"> Nervousness</td> <td align="center">4</td> <td align="center">(8)</td> <td align="center">2</td> <td align="center">(4)</td> <td align="center">15</td> <td align="center">(11)</td> </tr> <tr valign="top"> <td align="left"> Neuromuscular Disorder</td> <td align="center">1</td> <td align="center">(2)</td> <td align="center">5</td> <td align="center">(9)</td> <td align="center">4</td> <td align="center">(3)</td> </tr> <tr valign="top"> <td align="left">Skin and Appendages</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr valign="top"> <td align="left"> Alopecia</td> <td align="center">0</td> <td align="center">(0)</td> <td align="center">5</td> <td align="center">(9)</td> <td align="center">4</td> <td align="center">(3)</td> </tr> <tr valign="top"> <td align="left"> Androgen-Like Effects</td> <td align="center">2</td> <td align="center">(4)</td> <td align="center">3</td> <td align="center">(5)</td> <td align="center">24</td> <td align="center">(18)</td> </tr> <tr valign="top"> <td align="left"> Skin/Mucous Membrane Reaction</td> <td align="center">2</td> <td align="center">(4)</td> <td align="center">5</td> <td align="center">(9)</td> <td align="center">15</td> <td align="center">(11)</td> </tr> <tr valign="top"> <td align="left">Urogenital System</td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> <td align="center"> </td> </tr> <tr valign="top"> <td align="left"> Breast Changes/Pain/Tenderness</td> <td align="center">3</td> <td align="center">(6)</td> <td align="center">7</td> <td align="center">(13)</td> <td align="center">11</td> <td align="center">(8)</td> </tr> <tr valign="top"> <td align="left"> Menstrual Disorders</td> <td align="center">1</td> <td align="center">(2)</td> <td align="center">0</td> <td align="center">(0)</td> <td align="center">7</td> <td align="center">(5)</td> </tr> <tr valign="top"> <td styleCode="Botrule" align="left"> Vaginitis</td> <td styleCode="Botrule" align="center">10</td> <td styleCode="Botrule" align="center">(20)</td> <td styleCode="Botrule" align="center">8</td> <td styleCode="Botrule" align="center">(15)</td> <td styleCode="Botrule" align="center">11</td> <td styleCode="Botrule" align="center">(8)</td> </tr> <tr> <td colspan="7">* LD-Only = LUPRON DEPOT 3.75 mg</td> </tr> <tr> <td colspan="7">&#x2020; LD/N = LUPRON DEPOT 3.75 mg plus norethindrone acetate 5 mg</td> </tr> </tbody> </table>

<table ID="t2176811213" width="100%"> <caption>Table 4 MEAN PERCENT CHANGE FROM BASELINE IN BONE MINERAL DENSITY OF LUMBAR SPINE</caption> <colgroup> <col width="14*"/> <col width="14*"/> <col width="13*"/> <col width="14*"/> <col width="14*"/> <col width="14*"/> <col width="14*"/> </colgroup> <tbody> <tr> <td styleCode="Toprule"> </td> <td styleCode="Toprule" colspan="2" align="center"> <content styleCode="bold">LUPRON DEPOT 3.75mg</content> </td> <td styleCode="Toprule" colspan="4" align="center"> <content styleCode="bold">LUPRON DEPOT 3.75 mg plus norethindrone acetate 5 mg daily</content> </td> </tr> <tr> <td> </td> <td colspan="2" align="center"> <content styleCode="bold">Controlled Study</content> </td> <td colspan="2" align="center"> <content styleCode="bold">Controlled Study</content> </td> <td colspan="2" align="center"> <content styleCode="bold">Open Label Study</content> </td> </tr> <tr> <td styleCode="Toprule Botrule"> </td> <td styleCode="Toprule Botrule" align="center"> <content styleCode="bold">N</content> </td> <td styleCode="Toprule Botrule" align="center"> <content styleCode="bold">Change</content> <content styleCode="bold">(Mean, 95% CI)</content> <content styleCode="bold"> ^# </content> </td> <td styleCode="Toprule Botrule" align="center"> <content styleCode="bold">N</content> </td> <td styleCode="Toprule Botrule" align="center"> <content styleCode="bold">Change</content> <content styleCode="bold">(Mean, 95% CI)</content> <content styleCode="bold"> ^# </content> </td> <td styleCode="Toprule Botrule" align="center"> <content styleCode="bold">N</content> </td> <td styleCode="Toprule Botrule" align="center"> <content styleCode="bold">Change</content> <content styleCode="bold">(Mean, 95% CI)</content> <content styleCode="bold"> ^# </content> </td> </tr> <tr> <td align="left">Week 24*</td> <td align="center">41</td> <td align="center">-3.2% (-3.8, -2.6)</td> <td align="center">42</td> <td align="center">-0.3% (-0.8, 0.3)</td> <td align="center">115</td> <td align="center">-0.2% (-0.6, 0.2)</td> </tr> <tr> <td styleCode="Botrule" align="left">Week 52&#x2020;</td> <td styleCode="Botrule" align="center">29</td> <td styleCode="Botrule" align="center">-6.3% (-7.1, -5.4)</td> <td styleCode="Botrule" align="center">32</td> <td styleCode="Botrule" align="center">-1.0% (-1.9, -0.1)</td> <td styleCode="Botrule" align="center">84</td> <td styleCode="Botrule" align="center">-1.1% (-1.6, -0.5)</td> </tr> <tr> <td colspan="7">* Includes on-treatment measurements that fell within 2&#x2013;252 days after the first day of treatment.</td> </tr> <tr> <td colspan="7">&#x2020; Includes on-treatment measurements &gt;252 days after the first day of treatment.</td> </tr> <tr> <td colspan="7"> ^# 95% CI: 95% Confidence Interval</td> </tr> </tbody> </table>